Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 12:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 58 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: 4-aminopyridine (4-AP) Clear all
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Oral Fampridine-SR in Patients With Multiple Sclerosis

NCT00053417
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Placebo, 10 milligram (mg) fampridine-SR (4-aminopyridine, 4-AP), 15 mg fampridine-SR (4-aminopyridine, 4-AP), 20 mg fampridine-SR (4-aminopyridine, 4-AP)
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
23
States / cities
Phoenix, Arizona • Los Angeles, California • New Haven, Connecticut + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2011 · Synced Sep 28, 2026, 12:05 PM EDT
Recruiting Phase 1 Interventional

Preoperative Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor

NCT07171203
View directory record Official record
Conditions
Gastrointestinal Stromal Tumors
Interventions
Imatinib, Fampridine
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Sep 28, 2026, 12:05 PM EDT
Completed Phase 2 Interventional

Combination Therapy With Dalfampridine and Locomotor Training for Chronic, Motor Incomplete Spinal Cord Injury

NCT01621113
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Dalfampridine, Placebo
Drug
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 70 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 1, 2017 · Synced Sep 28, 2026, 12:05 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG

NCT03304054
View directory record Official record
Conditions
Myasthenia Gravis, Generalized
Interventions
Amifampridine Phosphate, Placebo Oral Tablet
Drug
Lead sponsor
Catalyst Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Cleveland, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 11, 2024 · Synced Sep 28, 2026, 12:05 PM EDT
Completed Phase 2 Interventional Results available

Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome

NCT01511978
View directory record Official record
Conditions
Lambert-Eaton Myasthenic Syndrome, Eaton-Lambert Myasthenic Syndrome
Interventions
Continuous 3,4-DAP, Taper 3,4-DAP to Placebo
Drug
Lead sponsor
Jacobus Pharmaceutical
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
7
States / cities
Sacramento, California • Indianapolis, Indiana • Durham, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2017 · Synced Sep 28, 2026, 12:05 PM EDT
Completed Phase 3 Interventional Results available

Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial

NCT00649792
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Fampridine-SR
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
38
States / cities
Phoenix, Arizona • Fayetteville, Arkansas • Berkeley, California + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2012 · Synced Sep 28, 2026, 12:05 PM EDT
Recruiting Phase 2 Interventional

4-Aminopyridine to Treat Skin Burns

NCT06596434
View directory record Official record
Conditions
Burns, Second Degree Burn, Wounds and Injuries
Interventions
Drug: 4-Aminopyridine, Placebo
Drug · Other
Lead sponsor
John Elfar
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Sep 28, 2026, 12:05 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Ampyra for Optic Neuritis in Multiple Sclerosis

NCT01337986
View directory record Official record
Conditions
Multiple Sclerosis, Optic Neuritis
Interventions
Dalfampridine/Placebo, Placebo/Dalfampridine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 29, 2020 · Synced Sep 28, 2026, 12:05 PM EDT
Terminated Phase 3 Interventional Results available

Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)

NCT03579966
View directory record Official record
Conditions
Myasthenia Gravis, MuSK, AChR Myasthenia Gravis
Interventions
Amifampridine Phosphate
Drug
Lead sponsor
Catalyst Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Cleveland, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 6, 2024 · Synced Sep 28, 2026, 12:05 PM EDT
Completed No phase listed Observational

Responsiveness to Dalfampridine-ER Treatment Among Multiple Sclerosis Patients

NCT01399957
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Mount Sinai Rehabilitation Hospital
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 9, 2015 · Synced Sep 28, 2026, 12:05 PM EDT
Completed Early Phase 1 Interventional

Effects of 4-AP on Functional SCI Recovery

NCT05447676
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Dalfampridine, Placebo drug, STDP stimulation, Exercise training
Drug · Other · Behavioral
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years to 85 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 28, 2026, 12:05 PM EDT
Completed Phase 1 Interventional

Effect of Amifampridine on Neuromuscular Transmission in Patients Treated With OnabotulinumtoxinA

NCT05769478
View directory record Official record
Conditions
Botulism, Iatrogenic Botulism
Interventions
Amifampridine
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 28, 2026, 12:05 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Oral Fampridine-SR for the Treatment of Spasticity Resulting From Spinal Cord Injury

NCT00041717
View directory record Official record
Conditions
Spinal Cord Injury, Muscle Spasticity
Interventions
Fampridine-SR, Placebo
Drug · Other
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
37
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Sep 28, 2026, 12:05 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Randomized Trial to Evaluate Ampyra for Gait Impairment in Parkinson's Disease

NCT01491022
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Ampyra first, then Placebo, placebo first, then Ampyra
Drug
Lead sponsor
University of Miami
Other
Eligibility
45 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 1, 2018 · Synced Sep 28, 2026, 12:05 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS)

NCT02970162
View directory record Official record
Conditions
Lambert-Eaton Myasthenic Syndrome
Interventions
Amifampridine Phosphate, Placebo Oral Tablet
Drug
Lead sponsor
Catalyst Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 23, 2018 · Synced Sep 28, 2026, 12:05 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)

NCT01377922
View directory record Official record
Conditions
Lambert Eaton Myasthenic Syndrome
Interventions
Amifampridine Phosphate, Placebo
Drug
Lead sponsor
Catalyst Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
6
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2018 · Synced Sep 28, 2026, 12:05 PM EDT
Completed Phase 3 Interventional Results available

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

NCT01328379
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Dalfampridine-ER 5mg, Dalfampridine-ER 10mg, Placebo
Drug · Other
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
70
States / cities
Cullman, Alabama • Phoenix, Arizona • Sun City, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2013 · Synced Sep 28, 2026, 12:05 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis

NCT02219932
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
fampridine, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 70 Years
Enrollment
646 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
17
States / cities
Cullman, Alabama • Phoenix, Arizona • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2017 · Synced Sep 28, 2026, 12:05 PM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Dalfampridine.

NCT02422940
View directory record Official record
Conditions
Post-ischemic Stroke
Interventions
dalfampridine-ER 7.5 mg, dalfampridine-ER 10 mg
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
62
States / cities
Gilbert, Arizona • Berkeley, California • Carlsbad, California + 54 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2019 · Synced Sep 28, 2026, 12:05 PM EDT
Completed Phase 3 Interventional Results available

Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR Tablets in Multiple Sclerosis Patients Who Participated in the MS-F203 Trial

NCT00648908
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Fampridine-SR
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
27
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2012 · Synced Sep 28, 2026, 12:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics (PK) of Dalfampridine-ER 7.5 mg BID in Healthy Volunteers and Subjects With Mild or Moderate Renal Impairment

NCT01316055
View directory record Official record
Conditions
Renal Insufficiency
Interventions
Dalfampridine-ER
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
2
States / cities
Anaheim, California • South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 6, 2012 · Synced Sep 28, 2026, 12:05 PM EDT
Recruiting Phase 2 Interventional

4-AP Peripheral Nerve Crossover Trial

NCT06003166
View directory record Official record
Conditions
Peripheral Nerve Injury, Crush Injury
Interventions
4-Aminopyridine, Placebo
Drug · Other
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 90 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 4, 2025 · Synced Sep 28, 2026, 12:05 PM EDT
Completed Phase 2 Interventional

Assessment of Chronic Guillain-Barre Syndrome Improvement With Use of 4-aminopyridine

NCT00056810
View directory record Official record
Conditions
Guillain-Barre Syndrome
Interventions
4-aminopyridine (4-AP)
Drug
Lead sponsor
FDA Office of Orphan Products Development
Federal
Eligibility
19 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Sep 28, 2026, 12:05 PM EDT
Completed Phase 3 Interventional Results available

Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis

NCT00654927
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Fampridine-SR b.i.d. (Twice Daily)
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
20
States / cities
Phoenix, Arizona • Los Angeles, California • Atlanta, Georgia + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2012 · Synced Sep 28, 2026, 12:05 PM EDT